Curis Inc CRIS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CRIS is a good fit for your portfolio.
News
-
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Curis to Present at Upcoming Healthcare Conferences in April
-
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)
-
Curis Provides Fourth Quarter 2023 Business Update
-
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
Trading Information
- Previous Close Price
- $14.77
- Day Range
- $14.07–14.82
- 52-Week Range
- $3.80–19.60
- Bid/Ask
- $13.50 / $14.77
- Market Cap
- $85.58 Mil
- Volume/Avg
- 10,246 / 31,183
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.67
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 49
- Website
- https://www.curis.com
Comparables
Valuation
|
Metric
|
CRIS
|
PRLD
|
CLDX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.35 | 0.94 | 4.82 |
Price/Sales | 7.67 | — | 260.58 |
Price/Cash Flow | — | — | — |
Price/Earnings
CRIS
PRLD
CLDX
Financial Strength
|
Metric
|
CRIS
|
PRLD
|
CLDX
|
|---|---|---|---|
Quick Ratio | 4.37 | 10.67 | 13.69 |
Current Ratio | 4.51 | 10.79 | 13.87 |
Interest Coverage | −23.94 | — | — |
Quick Ratio
CRIS
PRLD
CLDX
Profitability
|
Metric
|
CRIS
|
PRLD
|
CLDX
|
|---|---|---|---|
Return on Assets (Normalized) | −45.51% | −38.93% | −30.49% |
Return on Equity (Normalized) | −130.54% | −43.41% | −33.19% |
Return on Invested Capital (Normalized) | −120.60% | −42.59% | −32.85% |
Return on Assets
CRIS
PRLD
CLDX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Tjgnptjnb | Ttksq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Twdysxj | Kpnngt | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Knmgfhrzv | Qgpfy | $97.8 Bil | |
MRNA
| Moderna Inc | Sqpwrxmr | Sjfvc | $38.8 Bil | |
ARGX
| argenx SE ADR | Zftvmzfdy | Sfdlg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Fpjtjdm | Rvkww | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mchvbkkf | Qlsdztx | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Hnlkhkb | Qjxsw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mlrpjnlfp | Qcshbz | $12.5 Bil | |
INCY
| Incyte Corp | Cgdjxyym | Sdnsx | $11.5 Bil |